Medial Bone Plating for Management of Type V Central Tarsal Bone Fractures in Six Dogs

Veterinary and Comparative Orthopaedics and Traumatology ◽

10.1055/s-0040-1716502 ◽

2020 ◽

Author(s):

Tim G. Easter ◽

Jonathan J. Pink ◽

Bill Oxley ◽

Alexis Bilmont

Keyword(s):

Fracture Healing ◽

Bone Fractures ◽

Bone Plate ◽

Medial Malleolus ◽

Tarsal Bone ◽

Low Incidence ◽

External Trauma ◽

Type V

Abstract Objective The aim of this study was to report the surgical technique and outcomes of dogs with type V central tarsal bone (CTB) fractures stabilized with a bone plate applied to the medial aspect of the tarsus and metatarsus. Study Design This study was a retrospective review of dogs with type V CTB fractures diagnosed with computed tomography and stabilized using a medial bone plate. Follow-up included clinical examination and radiography 8 to 10 weeks postoperatively and/or a long-term owner questionnaire. Results Six dogs were identified. All fractures occurred during exercise without external trauma and all dogs had additional tarsal fractures. Five dogs returned for clinical follow-up; all had no or mild lameness and evidence of fracture healing on radiography. A suspected surgical site infection occurred in one dog and resolved with medical management. Suspected contact between the plate and medial malleolus in one dog, and loosening of a talar screw in another, were identified, though not treated. Five owners completed the questionnaire, a median of 88 months postoperatively. No further complications were reported, limb function was reportedly acceptable, and all owners were very satisfied with the surgery. Conclusion Medial bone plate stabilization of highly comminuted CTB fractures resulted in evidence of fracture healing, and a low incidence of complications in six non-racing dogs.

Download Full-text

THE CLASSIC TYPE OF EHLERS–DANLOS SYNDROME: DIFFERENTIAL DIAGNOSIS AND PECULIARITIES OF PATIENT MANAGEMENT

PEDIATRIA Journal named after G N SPERANSKY ◽

10.24110/0031-403x-2021-100-5-62-69 ◽

2021 ◽

Vol 100 (5) ◽

pp. 62-69

Author(s):

А.N. Semyachkina ◽

◽

E.А. Nikolaeva ◽

А.R. Zabrodina ◽

L.P. Melikyan ◽

...

Keyword(s):

Differential Diagnosis ◽

Adult Population ◽

Gene Mutations ◽

Hereditary Disease ◽

Ehlers Danlos Syndrome ◽

Severe Pathology ◽

Type V ◽

Danlos Syndrome

The Classic Ehlers–Danlos syndrome (cEDS) is an autosomal dominant hereditary disease caused by type V collagen defect. The incidence of pathology is estimated at 1:20,000 of the population. The results of a long-term (15 years) follow-up of a group of patients (n=18) with cEDS, including 5 boys and 13 girls aged from 3 to 18 years, are presented. The diagnosis was made based on the presence of 2 large and 5 small international diagnostic criteria in all patients. The progreduated character of the disease is shown, which is most obvious in the dynamics of the state of the musculoskeletal system. Genetic verification of the diagnosis was performed in 6 patients; 5 probands had mutations in the COL5A1 gene, and one in the COL5A2 gene. Mutations already registered in the database were detected only in 2 children. Previously unknown substitutions were found in 4 patients. The article presents the issues of differential diagnosis of this severe pathology and touches upon the issue of continuity between medical pediatric specialists and doctors of various specialties working with the adult population.

Download Full-text

Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study

10.1210/endo-meetings.2011.part3.p30.p3-284 ◽

2011 ◽

pp. P3-284-P3-284

Author(s):

AnneMarij G Burgers ◽

Nieke E Kokshoorn ◽

Alberto M Pereira ◽

Ferdinand Roelfsema ◽

Johannes WA Smit ◽

...

Keyword(s):

Adrenal Insufficiency ◽

Transsphenoidal Surgery ◽

Follow Up Study ◽

Long Term Follow Up ◽

Low Incidence

Download Full-text

Reliability of Wastewater Analysis for Monitoring COVID-19 Incidence Revealed by a Long-Term Follow-Up Study

Frontiers in Virology ◽

10.3389/fviro.2021.776998 ◽

2021 ◽

Vol 1 ◽

Author(s):

Rafael Sanjuán ◽

Pilar Domingo-Calap

Keyword(s):

Viral Genome ◽

Population Level ◽

Wastewater Analysis ◽

Disease Notification ◽

Follow Up Study ◽

Long Term Follow Up ◽

Low Incidence ◽

Rna Concentration

Wastewater-based epidemiology has been used for monitoring human activities and waterborne pathogens. Although wastewaters can also be used for tracking SARS-CoV-2 at the population level, the reliability of this approach remains to be established, especially for early warning of outbreaks. We collected 377 samples from different treatment plants processing wastewaters of >1 million inhabitants in Valencia, Spain, between April 2020 and March 2021. Samples were cleaned, concentrated, and subjected to RT-qPCR to determine SARS-CoV-2 concentrations. These data were compared with cumulative disease notification rates over 7 and 14 day periods. We amplified SARS-CoV-2 RNA in 75% of the RT-qPCRs, with an estimated detection limit of 100 viral genome copies per liter (gc/L). SARS-CoV-2 RNA concentration correlated strongly with disease notification rates over 14-day periods (Pearson r = 0.962, P < 0.001). A concentration >1000 gc/L showed >95% sensitivity and specificity as an indicator of more than 25 new cases per 100,000 inhabitants. Albeit with slightly higher uncertainty, these figures were reproduced using a 7-day period. Time series were similar for wastewaters data and declared cases, but wastewater RNA concentrations exhibited transient peaks that were not observed in declared cases and preceded major outbreaks by several weeks. In conclusion, wastewater analysis provides a reliable tool for monitoring COVID-19, particularly at low incidence values, and is not biased by asymptomatic cases. Moreover, this approach might reveal previously unrecognized features of COVID-19 transmission.

Download Full-text

Low Incidence of Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR LVAD System in the Long-term Follow-up

The International Journal of Artificial Organs ◽

10.5301/ijao.5000441 ◽

2015 ◽

Vol 38 (10) ◽

pp. 542-547 ◽

Cited By ~ 7

Author(s):

Attilio Iacovoni ◽

Paolo Centofanti ◽

Matteo Attisani ◽

Alessandro Verde ◽

Amedeo Terzi ◽

...

Keyword(s):

Gastrointestinal Bleeding ◽

Pump Thrombosis ◽

Long Term Follow Up ◽

Low Incidence

Download Full-text

Long-term outcomes of acromegaly treated with fractionated stereotactic radiation: case series and literature review

Neuro-Oncology Practice ◽

10.1093/nop/npx002 ◽

2017 ◽

Vol 4 (4) ◽

pp. 255-262

Author(s):

Ryan Rhome ◽

Isabelle M Germano ◽

Ren-Dih Sheu ◽

Sheryl Green

Keyword(s):

Systematic Review ◽

Literature Review ◽

Case Series ◽

Tumor Control ◽

Pituitary Neoplasms ◽

Review Of The Literature ◽

Biochemical Control ◽

Low Incidence

Abstract Background Growth hormone (GH)-secreting pituitary adenomas represent an uncommon subset of pituitary neoplasms. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) have been used as primary or adjuvant treatment. The purpose of this study is to report the long-term tumor control and toxicity from our institution and to perform a systematic literature review of acromegaly patients treated with FSRT. Methods We retrospectively reviewed all patients treated with FSRT (median dose 50.4 Gray [Gy], range 50.4–54 Gy) between 2005 and 2012 who had: 1) GH-secreting adenoma with persistently elevated insulin growth factor-1 (IGF-1) despite medical therapy and 2) clinical follow up >3 years after FSRT. Patients were treated with modern FSRT planning techniques. Biochemical control was defined as IGF-1 normalization. Systematic review of the literature was performed for FSRT in acromegaly. Results With a median follow-up of 80 months, radiographic control was achieved in all 11 patients and overall survival was 100%. Long-term biochemical control was achieved in 10 patients (90.9%) with either FSRT alone (36.4%) or FSRT with continued medical management (45.5%). No patient experienced new hypopituitarism, cranial nerve dysfunctions, or visual deficits. Our systematic review found published rates of biochemical control and hypopituitarism vary, with uniformly good radiographic control and low incidence of visual changes. Conclusions Adjuvant FSRT offered effective long-term biochemical control and radiographic control, and there was a lower rate of complications in this current series. Review of the literature shows variations in published rates of biochemical control after FSRT for acromegaly, but low incidence of serious toxicities.

Download Full-text

Surgical Repair of Ileovesical Fistulas: Long-term Complications, Quality of Life, and Patient Satisfaction

The American Surgeon ◽

10.1177/000313481408001221 ◽

2014 ◽

Vol 80 (12) ◽

pp. 1207-1211 ◽

Cited By ~ 3

Author(s):

Jeffrey W. Hastings ◽

Malika Garg ◽

Elizabeth T. Lynn ◽

Celia M. Divino

Keyword(s):

Quality Of Life ◽

Patient Satisfaction ◽

Statistical Significance ◽

Retrospective Chart Review ◽

Administrative Database ◽

Low Incidence ◽

Assess Quality

Ileovesical fistulas (IVFs) are an uncommon complication of Crohn's disease. The aim of this study is to compare long-term surgical outcomes, assess quality of life, and quantify patient satisfaction after IVF repair. A retrospective chart review followed by a prospective survey was carried out. Survey questions focused on patient satisfaction and quality of life after repair of IVF. Fifty-one patients were identified from an administrative database. Mean follow-up was 4.3 years with a response rate of 51 per cent. At the time of the study, 0 per cent mortality and 16 per cent morbidity were recorded. No recurrence was noted. There was no statistical significance in incidence of complications between laparoscopic and open surgery. Statistically significant differences in single-stage versus multistage operations were found in postoperative day of discharge ( P < 0.001) and patient satisfaction ( P = 0.049). Ninety-eight per cent of patients reported extreme satisfaction with their surgery and an improvement in quality of life. A low incidence of morbidity and recurrence supports early surgical intervention in IVFs.

Download Full-text

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.6_suppl.32 ◽

2020 ◽

Vol 38 (6_suppl) ◽

pp. 32-32

Author(s):

Celestia S. Higano ◽

Fred Saad ◽

A. Oliver Sartor ◽

Kurt Miller ◽

Peter Conti ◽

...

Keyword(s):

Bone Marrow ◽

Clinical Practice ◽

Observational Study ◽

Clinical Outcomes ◽

Bone Fractures ◽

Bone Marrow Suppression ◽

Routine Clinical Practice ◽

Metastatic Sites

32 Background: Ra-223 is a targeted alpha therapy that showed a survival advantage and favorable safety profile in the phase 3 ALSYMPCA trial in pts with mCRPC. REASSURE (NCT02141438) is evaluating the long-term safety of Ra-223 in routine clinical practice in pts with mCRPC over a 7-year follow-up period. Methods: In this global, prospective, single-arm, observational study, the second prespecified interim analysis (data cut-off March 2019) evaluated safety and clinical outcomes of Ra-223 in pts with mCRPC. Primary outcome measures were incidence of second primary malignancies (SPM), bone marrow suppression and short- and long-term safety in pts who had ≥1 Ra-223 dose. Secondary outcomes included overall survival (OS). Results: For 1465 pts in the safety analysis, median follow up was 11.5 months. Median PSA (n=1053), ALP (n=1048), and LDH (n=555) levels at baseline were 59 ng/mL, 135 U/L, and 269 U/L, respectively. 81% of pts had bone metastases only at baseline; 19% of pts had other metastatic sites, mostly in the lymph nodes. 19% of pts had <6 metastatic sites, 47% had 6–20 sites, 20% had >20 lesions but not a superscan, and 6% had a superscan. 45%, 38%, 37%, 9%, and 8% of pts received prior abiraterone, docetaxel, enzalutamide, cabazitaxel, or sipuleucel-T as prior therapies, respectively. Median number of Ra-223 doses received was 6; 67% of pts had ≥5 doses. SPM occurred in 1% of pts. The most common treatment-emergent drug-related adverse event (AE) of any grade was diarrhea (11%). 10% of pts had a bone-associated event, 5% had fractures, and 15% had a hematological AE. Median OS was 15.6 months (95% CI 14.6–16.5). Conclusions: In REASSURE, there was a low incidence of SPM, bone fractures, and bone marrow suppression after Ra-223 treatment, with no new AEs identified. This study confirms that in routine clinical practice, Ra-223 AE rates were low, and pts generally received ≥5 doses. Clinical trial information: NCT02141438. [Table: see text]

Download Full-text